What Ligand Pharmaceuticals (LGND) Said on Its Q3 Earnings Call

Ligand Pharmaceuticals NASDAQ: LGND reported third-quarter royalty revenue growth of 51% year over year to approximately $70 million, driven by Filspari, Ohtuvayre and commercial assets acquired through its July purchase of XOMA Royalty. The company also raised its full-year adjusted diluted earnings-per-share outlook while maintaining its revenue guidance.

MarketBeat • 5 hours ago

Ligand Reports Third Quarter 2026 Financial Results

Third-quarter royalty revenue up  51% year-over-year to $70.3 million Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75, from $9.00 to $9.50 1 ; Reaffirms Revenue Guidance Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla.

GlobeNewsWire • 13 hours ago

Ligand to Participate in November Investor Conferences

JUPITER, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: UBS Global Healthcare Conference.

GlobeNewsWire • Oct 27, 2026

Ligand to Host Investor Day on December 8, 2026

JUPITER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place on Tuesday, December 8, 2026 from 10:30 a.m. to 12:00 p.m. ET at the Harvard Club of New York City at 35 West 44th Street, New York, NY 10036.

GlobeNewsWire • Oct 22, 2026

Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026

JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29, 2026.

GlobeNewsWire • Oct 15, 2026

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million.

GlobeNewsWire • Sep 24, 2026

Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea® from Sydnexis for $23 Million

Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East, and Africa JUPITER, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has acquired an ascending tiered royalty interest in Santen Pharmaceutical Co., Ltd.

GlobeNewsWire • Sep 22, 2026

Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Healthcare Partners ("Signet"), with significant participation from existing investors 1315 Capital, Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), LDV Partners, and Agent Capital.

PRNewsWire • Sep 22, 2026

Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®

DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced an agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to sell its royalty rights associated with net sales of Ryjunea® in Europe, the Middle East, and Africa (EMEA). Under the terms of the agreement, Ligand will pay $23 million upfront to acquire a 100% interest in certain payments an.

Business Wire • Sep 22, 2026

Ligand Pharmaceuticals: Owning It Gives You A Stake Across Biotech

Ligand Pharmaceuticals (LGND) is reassessed after a ~10% loss since its last 'Buy' rating. The article focuses on LGND's future prospects, emphasizing its key royalty producing assets. LGND is highlighted as a reliable midcap pharma with a high-growth business model.

Seeking Alpha • Sep 18, 2026